Mutated Allele Fraction(MAF) of Epigenetically Driven

Target Genes, A Biomarker Assay to Support Clinical

Management in Solid Tumors Treated with Multi

Targeted Epigenetic Therapy(MTET)

Mohammad Amin Nezami

Research Protocol

Mutated Allele Fraction(MAF) of Epigenetically Driven Target Genes, A Biomarker Assay to Support Clinical Management in Solid Tumors Treated with Multi Targeted Epigenetic Therapy(MTET)

Mohammad Amin Nezami*

President and CEO, Sahel Oncology LLC, Pacific Medical Center of Hope, USA

Corresponding Author

Received Date: September 13, 2019; Published Date: September 16, 2019

Abstract

Our current understanding of the epigenetic science has transformed our ability to deliver therapies more precisely to the epigenetic targets driving the tumor growth and disrupting its behavior. In concert with our efforts to regulate the transcription of altered genes involved in tumor biology, we have emphasized a range of epigenetically regulated genes that control the tumor key molecular targets, involved with its growth and metastasis.

Keywords: Multi targeted epigenetic therapy; liquid biopsy; circulating DNA

Article Details

Citation

Mohammad Amin Nezami. Mutated Allele Fraction(MAF) of Epigenetically Driven Target Genes, A Biomarker Assay to Support Clinical Management in Solid Tumors Treated with Multi Targeted Epigenetic Therapy(MTET). Adv Can Res & Clinical Imag. 2(2): 2019. ACRCI.MS.ID.000532.